IMPAACT 2017 (MOCHA) and IMPAACT 2036 (CRAYON) Studies: Making HIV Treatment Easier for Kids & Teens
Simplifying HIV Treatment for Children and Adolescents. Managing HIV can be challenging for children and teenagers, especially when it comes to taking daily pills. The IMPAACT 2017 and IMPAACT 2036 studies are working to simplify HIV treatment by introducing long-acting injectable (LAI) antiretrovirals (ARVs), specifically Cabotegravir and Rilpivirine. After an initial treatment period with oral medications, participants receive LAIs every two months in the IMPAACT 2017 study and monthly in the IMPAACT 2036 study.
Long-acting injectables provide a more manageable treatment option for young people living with HIV, significantly improving their quality of life. Initial findings from IMPAACT 2017 demonstrate that these injectables are safe, effective, and preferred by adolescents over daily pills. IMPAACT 2036 will further refine dosing guidelines based on different weight categories, simplifying the prescribing process once LAIs are more widely available.
Who Benefits?
- Young people aged 12 to 17 years.
- Children aged 2 to under 12 years.
Through these studies, we are making HIV treatment more accessible, helping children and adolescents lead healthier, longer, and happier lives.
Discover more about these groundbreaking studies: IMPAACT2017 IMPAACT 2036
